- Home
- AUPH vs EVT Comparison
AUPH vs EVT Comparison
Compare AUPH & EVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUPH | EVT |
|---|---|---|
| Founded | 1993 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2014 | 2003 |
Fundamental Metrics
Financial Performance| Metric | AUPH | EVT |
|---|---|---|
| Price | $15.44 | $27.86 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $17.25 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 89.6K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5075.00 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $283,055,000.00 | N/A |
| Revenue This Year | $17.54 | N/A |
| Revenue Next Year | $15.74 | N/A |
| P/E Ratio | $61.40 | ★ N/A |
| Revenue Growth | ★ 20.38 | N/A |
| 52 Week Low | $8.80 | $23.00 |
| 52 Week High | $19.25 | $27.96 |
Technical Indicators
Market Signals| Indicator | AUPH | EVT |
|---|---|---|
| Relative Strength Index (RSI) | 44.99 | 61.67 |
| Support Level | $15.43 | $26.98 |
| Resistance Level | $16.38 | $27.96 |
| Average True Range (ATR) | 0.55 | 0.39 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 29.59 | 82.83 |
Price Performance
Historical ComparisonAbout AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.